In vitro characterization of PlyE146, a novel phage lysin that targets Gram-negative bacteria

PLoS ONE

Volumn 13, Issue 2, 2018, Pages

  Larpin, Yu ^a   Oechslin, Frank ^a   Moreillon, Philippe ^a   Resch, Grégory ^a   Entenza, José Manuel ^a   Mancini, Stefano ^a,b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; PLYE146 PROTEIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ENDO-N-ACETYLMURAMIDASE; GLYCOSIDASE;

ACINETOBACTER BAUMANNII; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; LACTOCOCCUS LACTIS; MOLECULAR WEIGHT; NONHUMAN; PROPHAGE; PROTEIN PURIFICATION; PSEUDOMONAS AERUGINOSA; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; COLIPHAGE; DRUG EFFECTS; METABOLISM;

ANTI-BACTERIAL AGENTS; BLOTTING, WESTERN; COLIPHAGES; GLYCOSIDE HYDROLASES; GRAM-NEGATIVE BACTERIA; MICROSCOPY, ELECTRON, TRANSMISSION;

EID: 85041378010     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0192507     Document Type: Article

References (27)

1. Spellberg B (2008) Antibiotic resistance and antibiotic development. Lancet Infect Dis 8: 211–212; author reply 212–214. https://doi.org/10.1016/S1473-3099(08)70048-3 PMID: 18353258
2. Poirel L, Kieffer N, Liassine N, Thanh D, Nordmann P (2016) Plasmid-mediated carbapenem and colis-tin resistance in a clinical isolate of Escherichia coli. Lancet Infect Dis 16: 281.
3. Potron A, Poirel L, Nordmann P (2015) Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology. Int J Antimicrob Agents 45: 568–585. https://doi.org/10.1016/j.ijantimicag.2015.03.001 PMID: 25857949
4. Schmelcher M, Donovan DM, Loessner MJ (2012) Bacteriophage endolysins as novel antimicrobials. Future Microbiol 7: 1147–1171. https://doi.org/10.2217/fmb.12.97 PMID: 23030422
5. Nelson DC, Schmelcher M, Rodriguez-Rubio L, Klumpp J, Pritchard DG, et al. (2012) Endolysins as antimicrobials. Adv Virus Res 83: 299–365. https://doi.org/10.1016/B978-0-12-394438-2.00007-4PMID: 22748813
6. Pastagia M, Schuch R, Fischetti VA, Huang DB (2013) Lysins: the arrival of pathogen-directed anti-infectives. J Med Microbiol 62: 1506–1516. https://doi.org/10.1099/jmm.0.061028-0 PMID: 23813275
7. Loessner MJ (2005) Bacteriophage endolysins—current state of research and applications. Curr Opin Microbiol 8: 480–487. https://doi.org/10.1016/j.mib.2005.06.002 PMID: 15979390
8. Briers Y, Walmagh M, Grymonprez B, Biebl M, Pirnay JP, et al. (2014) Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa. Antimicrob Agents Chemother 58: 3774–3784. https://doi.org/10.1128/AAC.02668-14 PMID: 24752267
9. Defraine V, Schuermans J, Grymonprez B, Govers SK, Aertsen A, et al. (2016) Efficacy of artilysin Art-175 against resistant and persistent Acinetobacter baumannii. Antimicrob Agents Chemother 60: 3480–3488. https://doi.org/10.1128/AAC.00285-16 PMID: 27021321
10. Jado I, Lopez R, Garcia E, Fenoll A, Casal J, et al. (2003) Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J Antimicrob Chemother 52: 967–973. https://doi.org/10.1093/jac/dkg485 PMID: 14613958
11. Fischetti VA (2010) Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens. Int J Med Microbiol 300: 357–362. https://doi.org/10.1016/j.ijmm.2010.04.002 PMID: 20452280
12. Jun SY, Jung GM, Yoon SJ, Oh MD, Choi YJ, et al. (2013) Antibacterial properties of a pre-formulated recombinant phage endolysin, SAL-1. Int J Antimicrob Agents 41: 156–161. https://doi.org/10.1016/j.ijantimicag.2012.10.011 PMID: 23276502
13. Oechslin F, Daraspe J, Giddey M, Moreillon P, Resch G (2013) In vitro characterization of PlySK1249, a novel phage lysin, and assessment of its antibacterial activity in a mouse model of Streptococcus aga-lactiae bacteremia. Antimicrob Agents Chemother 57: 6276–6283. https://doi.org/10.1128/AAC.01701-13 PMID: 24100496
14. Hermoso JA, Garcia JL, Garcia P (2007) Taking aim on bacterial pathogens: from phage therapy to enzybiotics. Curr Opin Microbiol 10: 461–472. https://doi.org/10.1016/j.mib.2007.08.002 PMID: 17904412
15. Junn HJ, Youn J, Suh KH, Lee SS (2005) Cloning and expression of Klebsiella phage K11 lysozyme gene. Protein Expr Purif 42: 78–84. https://doi.org/10.1016/j.pep.2005.03.026 PMID: 15882950
16. Briers Y, Walmagh M, Lavigne R (2011) Use of bacteriophage endolysin EL188 and outer membrane permeabilizers against Pseudomonas aeruginosa. J Appl Microbiol 110: 778–785. https://doi.org/10.1111/j.1365-2672.2010.04931.x PMID: 21241420
17. Lai MJ, Lin NT, Hu A, Soo PC, Chen LK, et al. (2011) Antibacterial activity of Acinetobacter baumannii phage varphiAB2 endolysin (LysAB2) against both gram-positive and gram-negative bacteria. Appl Microbiol Biotechnol 90: 529–539. https://doi.org/10.1007/s00253-011-3104-y PMID: 21264466
18. Huang G, Shen X, Gong Y, Dong Z, Zhao X, et al. (2014) Antibacterial properties of Acinetobacter baumannii phage Abp1 endolysin (PlyAB1). BMC Infect Dis 14: 681. https://doi.org/10.1186/s12879-014-0681-2 PMID: 25495514
19. Lood R, Winer BY, Pelzek AJ, Diez-Martinez R, Thandar M, et al. (2015) Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model. Antimicrob Agents Chemother 59: 1983–1991. https://doi.org/10.1128/AAC.04641-14 PMID: 25605353
20. Lai MJ, Soo PC, Lin NT, Hu A, Chen YJ, et al. (2013) Identification and characterisation of the putative phage-related endolysins through full genome sequence analysis in Acinetobacter baumannii ATCC 17978. Int J Antimicrob Agents 42: 141–148. https://doi.org/10.1016/j.ijantimicag.2013.04.022 PMID: 23742833
21. Thandar M, Lood R, Winer BY, Deutsch DR, Euler CW, et al. (2016) Novel engineered peptides of a phage lysin as effective antimicrobials against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 60: 2671–2679. https://doi.org/10.1128/AAC.02972-15 PMID: 26856847
22. Briers Y, Walmagh M, Van Puyenbroeck V, Cornelissen A, Cenens W, et al. (2014) Engineered endolysin-based "Artilysins" to combat multidrug-resistant gram-negative pathogens. MBio 5: e01379–01314. https://doi.org/10.1128/mBio.01379-14 PMID: 24987094
23. Yang H, Wang M, Yu J, Wei H (2015) Antibacterial activity of a novel peptide-modified lysin against Acinetobacter baumannii and Pseudomonas aeruginosa. Front Microbiol 6: 1471. https://doi.org/10.3389/fmicb.2015.01471 PMID: 26733995
24. Ma Q, Guo Z, Gao C, Zhu R, Wang S, et al. (2017) Enhancement of the direct antimicrobial activity of Lysep3 against Escherichia coli by inserting cationic peptides into its C terminus. Antonie Van Leeuwenhoek 110: 347–355. https://doi.org/10.1007/s10482-016-0806-2 PMID: 27943012
25. Broskey NT, Daraspe J, Humbel BM, Amati F (2013) Skeletal muscle mitochondrial and lipid droplet content assessed with standardized grid sizes for stereology. J Appl Physiol (1985) 115: 765–770.
26. Zhang Y (2008) I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 9: 40. https://doi.org/10.1186/1471-2105-9-40 PMID: 18215316
27. Roy A, Kucukural A, Zhang Y (2010) I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 5: 725–738. https://doi.org/10.1038/nprot.2010.5 PMID: 20360767